MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer-Reference-Cited by-同舟云学术

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer

Published:2014-05-21 Issue:3 Volume:233 Page:308-318
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Liu Guoyan¹²,Sun Yan¹³,Ji Ping¹,Li Xia¹⁴,Cogdell David¹,Yang Da¹,Parker Kerrigan Brittany C¹,Shmulevich Ilya⁵,Chen Kexin³⁶,Sood Anil K⁷⁸⁹,Xue Fengxia²,Zhang Wei¹⁹

Affiliation:

1. Department of Pathology; University of Texas MD Anderson Cancer Center; Houston TX USA

2. Department of Gynecology and Obstetrics; Tianjin Medical University General Hospital; People's Republic of China

3. Department of Pathology; Tianjin Medical University Cancer Institute and Hospital; People's Republic of China

4. Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology; Fourth Military Medical University; Xi'an People's Republic of China

5. Institute for Systems Biology; Seattle WA USA

6. Department of Epidemiology and Biostatistics; Tianjin Medical University Cancer Institute and Hospital; People's Republic of China

7. Department of Gynecologic Oncology and Reproductive Medicine; University of Texas MD Anderson Cancer Center; Houston TX USA

8. Department of Cancer Biology; University of Texas MD Anderson Cancer Center; Houston TX USA

9. Center for RNAi and Non-Coding RNA; University of Texas MD Anderson Cancer Center; Houston TX USA

Funder

National Institutes of Health

National Key Scientific and Technological Project

Tianjin Science and Technology Committee Foundation

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/path.4348/fullpdf

Reference37 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer;Heintz;Int J Gynaecol Obstet,2006

3. Clinical practice. Screening for ovarian cancer;Clarke-Pearson;N Engl J Med,2009

4. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data;Coleman;Lancet,2011

5. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents;Dinh;Crit Rev Oncol Hematol,2008

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stable Dual miR-143 and miR-506 Upregulation Inhibits Proliferation and Cell Cycle Progression;International Journal of Molecular Sciences;2024-04-17

2. miRNAs in pancreatic cancer progression and metastasis;Clinical & Experimental Metastasis;2024-01-19

3. A senescence-like state is beneficial for ovarian cancer treatment;2023-10-02

4. SUZ12 promotes the malignant behavior of gastric cancer cells by CDKs;Journal of Biochemical and Molecular Toxicology;2023-03-30

5. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs;Breast Cancer Research and Treatment;2023-02-27